Cadrenal Therapeutics, Valuation
| CVKD Stock | 14.99 0.98 7.00% |
At this time, the firm appears to be overvalued. Cadrenal Therapeutics, shows a prevailing Real Value of USD8.57 per share. The current price of the firm is USD14.99. Our model approximates the value of Cadrenal Therapeutics, from analyzing the firm fundamentals such as return on equity of -1.25, and Current Valuation of 20.5 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Cadrenal Therapeutics,'s valuation include:
Price Book 7.2868 | Enterprise Value 20.5 M | Enterprise Value Ebitda 0.2128 |
Overvalued
Today
Please note that Cadrenal Therapeutics,'s price fluctuation is relatively risky at this time. Calculation of the real value of Cadrenal Therapeutics, is based on 3 months time horizon. Increasing Cadrenal Therapeutics,'s time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Cadrenal stock is determined by what a typical buyer is willing to pay for full or partial control of Cadrenal Therapeutics, Common. Since Cadrenal Therapeutics, is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cadrenal Stock. However, Cadrenal Therapeutics,'s intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 14.99 | Real 8.57 | Target 3.0 | Hype 16.64 | Naive 13.2 |
The real value of Cadrenal Stock, also known as its intrinsic value, is the underlying worth of Cadrenal Therapeutics, Company, which is reflected in its stock price. It is based on Cadrenal Therapeutics,'s financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Cadrenal Therapeutics,'s stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Cadrenal Therapeutics, Common helps investors to forecast how Cadrenal stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cadrenal Therapeutics, more accurately as focusing exclusively on Cadrenal Therapeutics,'s fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Cadrenal Therapeutics,'s intrinsic value based on its ongoing forecasts of Cadrenal Therapeutics,'s financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Cadrenal Therapeutics,'s closest peers. If more than one evaluation category is relevant for Cadrenal Therapeutics, we suggest using both methods to arrive at a better estimate.
Cadrenal Valuation Trend
Comparing Cadrenal Therapeutics,'s enterprise value against its market capitalization is a good way to estimate the value of Cadrenal Therapeutics, Common uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Cadrenal Therapeutics, Total Value Analysis
Cadrenal Therapeutics, Common is currently forecasted to have valuation of 20.5 M with market capitalization of 24.86 M, debt of 21.35 K, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Cadrenal Therapeutics, fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
20.5 M | 24.86 M | 21.35 K |
Cadrenal Therapeutics, Asset Utilization
One of the ways to look at asset utilization of Cadrenal is to check how much profit was generated for every dollar of assets it reports. Cadrenal Therapeutics, Common shows a negative utilization of assets of -0.71 percent, losing USD0.007099 for each dollar of assets held by the firm. Unsuccessful asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Cadrenal Therapeutics, Common shows how unproductive it operates for each dollar spent on its assets.Cadrenal Therapeutics, Ownership Allocation
Cadrenal Therapeutics, Common retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.Cadrenal Therapeutics, Profitability Analysis
Net Loss for the year was (8.36 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Cadrenal Therapeutics,'s worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Cadrenal Therapeutics, and how it compares across the competition.
About Cadrenal Therapeutics, Valuation
The stock valuation mechanism determines Cadrenal Therapeutics,'s current worth on a weekly basis. Our valuation model uses a comparative analysis of Cadrenal Therapeutics,. We calculate exposure to Cadrenal Therapeutics,'s market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cadrenal Therapeutics,'s related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -2 K | -2.1 K |
Cadrenal Therapeutics, Growth Indicators
Investing in growth stocks can be very risky. If the company such as Cadrenal Therapeutics, does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 13.5 M |
Cadrenal Therapeutics, Current Valuation Indicators
Valuation refers to the process of determining the present value of Cadrenal Therapeutics, Common and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Cadrenal we look at many different elements of the entity such as Cadrenal's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Cadrenal Therapeutics,, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Cadrenal Therapeutics,'s valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Cadrenal Therapeutics,'s worth.Complementary Tools for Cadrenal Stock analysis
When running Cadrenal Therapeutics,'s price analysis, check to measure Cadrenal Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cadrenal Therapeutics, is operating at the current time. Most of Cadrenal Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Cadrenal Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cadrenal Therapeutics,'s price. Additionally, you may evaluate how the addition of Cadrenal Therapeutics, to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |